Oscar Health stock has delivered a very large 3-year gain, yet the broader valuation checks paint a more mixed picture, with the shares currently screening as undervalued on market multiples but only middling on a composite value score.

• Over the last 3 years, Oscar Health has returned roughly 2.8x an investor's starting position. This puts recent moves in a longer-term context that matters for today's entry price.
• Expectations around how efficiently Oscar Health can scale its insurance platform may support the current valuation. At the same time, execution risk on controlling medical and operating costs could limit how much investors are willing to pay for that growth.
• The company passes half of Simply Wall St's valuation checks, with a mixed score of 3 out of 6, which suggests neither a clear bargain nor an obviously stretched valuation.

The issue now is whether Oscar Health's recent share price level still offers an attractive entry point after such a strong multi-year run.

Does Oscar Health Look Undervalued on Sales?

P/S is a useful check for Oscar Health because investors are still weighing the value of its revenue base relative to more mature insurers that are easier to compare on earnings. On this measure, Oscar Health trades on a P/S of about 0.6x, which is below both the Insurance industry average of roughly 1.2x and a peer average near 1.3x. That places the stock at a discount to what the market is currently paying for each dollar of sales in comparable insurance businesses.

A P/S ratio of about 0.8x can be used as a reference point that blends Oscar Health's profile with sector norms, which is higher than the current 0.6x level. This gap suggests that, even after its 3 year share price performance, the stock price does not fully match the sales multiple implied by this framework. Investors are effectively paying less for Oscar Health's revenue stream than this model indicates could be reasonable based on its risk and business characteristics.

On the P/S yardstick, Oscar Health stock appears undervalued relative to this reference multiple and the wider insurance sector.

The Oscar Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Oscar Health pick up where this valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would line up with a share price that is much higher or lower than today. Each narrative links its implied number to a clear view on how Oscar Health's revenue growth, profitability and key risks might evolve, giving you something concrete to test and revisit as fresh information comes through.

The community is split on Oscar Health, with one camp focused on upside from its ACA focused model and another zeroing in on execution and regulatory risks.

Bull case: 18% undervalued

"Oscar's strategic entry into the ICHRA ecosystem, now amplified by proprietary marketplace assets and the partnership with a leading US retailer, positions the company to rapidly capture share from traditional group and supplemental products…"

Bear case: 117% overvalued

"Persistently high and rising medical loss ratios, now over 91 percent, coupled with a market-wide morbidity increase, threaten Oscar Health's path to sustainable profitability…"

Do you think there's more to the story for Oscar Health? Head over to our Community to see what others are saying!

The Bottom Line

Oscar Health screens as undervalued on sales multiples, yet broader checks land in mixed territory, so the stock does not look like a straightforward bargain. The key question is whether management can translate its insurance platform into sustainably better margins without letting medical or operating costs run ahead of expectations. If that happens, today’s discount to peers could look conservative, but if execution stumbles, the lower multiple may simply be the market pricing in those risks. For now, the crux of the Oscar Health debate is whether its cost discipline can keep up with its growth ambitions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.